Nonalcoholic Fatty Liver Disease: Pathology and Pathog

Annual Review of Pathology: Mechanisms of Disease
5, 145-171
DOI: 10.1146/annurev-pathol-121808-102132

Citation Report

#	Article	IF	Citations
1	AMELIORATING EFFECT OF ALLIUM SATIVUM ON HIGH-FAT DIET INDUCED FATTY LIVER IN ALBINO RATS. Pakistan Journal of Medical Sciences, 1969, 32, 403-7.	0.3	3
2	Nonalcoholic fatty liver disease in children. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 397-402.	1.3	34
3	Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 709-714.	1.3	63
4	Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010, 52, 1836-1846.	3.6	1,857
5	Metaâ€analysis: insulin sensitizers for the treatment of nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2010, 32, 1211-1221.	1.9	139
6	Nature vs nurture: genetic susceptibility and weight loss in hepatic steatosis. Clinical Genetics, 2010, 78, 422-423.	1.0	1
7	Roles of liver innate immune cells in nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2010, 16, 4652.	1.4	82
8	Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. American Journal of Clinical Nutrition, 2010, 92, 1522-1527.	2.2	175
9	Fibrosis in the Liver. Progress in Molecular Biology and Translational Science, 2010, 97, 151-200.	0.9	29
10	The involvement of microRNAs in TypeÂ2 diabetes. Biochemical Society Transactions, 2010, 38, 1565-1570.	1.6	87
11	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 272-282.	0.4	202
12	Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2010, 82, 211-218.	1.0	69
13	Metabolomic Assessment of the Effect of Dietary Cholesterol in the Progressive Development of Fatty Liver Disease. Journal of Proteome Research, 2010, 9, 2527-2538.	1.8	141
14	Pathology of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 195-203.	8.2	417
15	Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opinion on Drug Discovery, 2011, 6, 995-1025.	2.5	20
16	Computer-Based Image Analysis of Liver Steatosis with Large-Scale Microscopy Imagery and Correlation with Magnetic Resonance Imaging Lipid Analysis. , 2011, , .		13
17	Animal models of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 35-44.	8.2	399
18	Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology and Hepatology, 2011, 5, 189-200.	1.4	72

#	Article	IF	Citations
19	Hepatic Incidentalomas. Radiologic Clinics of North America, 2011, 49, 291-322.	0.9	20
20	Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metabolism Reviews, 2011, 43, 317-334.	1.5	136
21	Insulin Resistance and Other Metabolic Risk Factors in the Pathogenesis of Hepatocellular Carcinoma. Clinics in Liver Disease, 2011, 15, 281-296.	1.0	54
23	Protease-Activated Receptor 1 and Hematopoietic Cell Tissue Factor Are Required for Hepatic Steatosis in Mice Fed a Western Diet. American Journal of Pathology, 2011, 179, 2278-2289.	1.9	39
24	In vitro and in vivo safety assessment of edible blue-green algae, Nostoc commune var. sphaeroides KÃ¼tzing and Spirulina plantensis. Food and Chemical Toxicology, 2011, 49, 1560-1564.	1.8	49
25	Whey protein isolate protects against diet-induced obesity and fatty liver formation. International Dairy Journal, 2011, 21, 513-522.	1.5	28
26	Cysteine aggravates palmitate-induced cell death in hepatocytes. Life Sciences, 2011, 89, 878-885.	2.0	11
27	Hepatic Steatosis and Diabetes Mellitus: Risk Factors, Pathophysiology and with its Clinical Implications: A Hospital Based Case Control Study in Western Region of Nepal. Journal of College of Medical Sciences-Nepal, 2011, 1, 51-56.	0.2	4
28	Distinct Effects of Calorie Restriction and Resveratrol on Diet-Induced Obesity and Fatty Liver Formation. Journal of Nutrition and Metabolism, 2011, 2011, 1-10.	0.7	71
29	Nutritional recommendations for patients with non-alcoholic fatty liver diseases. World Journal of Gastroenterology, 2011, 17, 3375.	1.4	13
30	Association between Markers of Fatty Liver Disease and Impaired Glucose Regulation in Men and Women from the General Population: The KORA-F4-Study. PLoS ONE, 2011, 6, e22932.	1.1	57
31	Upregulation of Hemoglobin Expression by Oxidative Stress in Hepatocytes and Its Implication in Nonalcoholic Steatohepatitis. PLoS ONE, 2011, 6, e24363.	1.1	101
32	New genes involved in hepatic steatosis. Current Opinion in Lipidology, 2011, 22, 159-164.	1.2	19
33	Keratin 18, Apoptosis, and Liver Disease in Children. Current Pediatric Reviews, 2011, 7, 310-315.	0.4	4
34	Does physical inactivity cause nonalcoholic fatty liver disease?. Journal of Applied Physiology, 2011, 111, 1828-1835.	1.2	74
35	Elevated Peripheral Blood Monocyte Fraction in Nonalcoholic Fatty Liver Disease. Tohoku Journal of Experimental Medicine, 2011, 223, 227-233.	0.5	15
36	Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease. Experimental and Therapeutic Medicine, 2011, 2, 1077-1081.	0.8	78
37	Plasma reactive carbonyl species levels and risk of nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1010-1015.	1.4	27

#	Article	IF	Citations
38	Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis. Laboratory Investigation, 2011, 91, 1107-1117.	1.7	53
39	Attenuation of Fatty Liver and Prevention of Hypercholesterolemia by Extract ofâ€‚Curcuma longaâ€‚through Regulating the Expression of CYP7A1, LDLâ€Receptor, HOâ€1, and HMGâ€CoA Reductase. Journal of Food Science, 2011, 76, H80-9.	1.5	51
40	Histopathological evaluation of fatty and alcoholic liver diseases. Journal of Digestive Diseases, 2011, 12, 17-24.	0.7	24
41	Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. BioFactors, 2011, 37, 8-16.	2.6	115
43	Oleate-mediated activation of phospholipase D and mammalian target of rapamycin (mTOR) regulates proliferation and rapamycin sensitivity of hepatocarcinoma cells. Diabetologia, 2011, 54, 954-964.	2.9	17
44	Role of Cytokines in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. Indian Journal of Clinical Biochemistry, 2011, 26, 202-209.	0.9	82
45	Liver methylene fraction by dualâ€•and tripleâ€•echo gradientâ€•echo imaging at 3.0T: Correlation with proton MR spectroscopy and estimation of robustness after SPIO administration. Journal of Magnetic Resonance Imaging, 2011, 33, 119-127.	1.9	12
46	Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology, 2011, 54, 133-144.	3.6	528
47	Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis in cdipt-deficient zebrafish. Hepatology, 2011, 54, 452-462.	3.6	71
48	Non-alcoholic fatty liver disease: what's new under the microscope?. Gut, 2011, 60, 1152-1158.	6.1	31
49	Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologistâ€™s perspective. Expert Review of Gastroenterology and Hepatology, 2011, 5, 223-231.	1.4	61
50	Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2011, 12, 1901-1911.	0.9	13
51	Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterology, 2011, 2011, 1-11.	1.5	113
52	Liver Tissue Engineering. , 2011, , 389-419.		7
53	Fatty acid regulation of hepatic lipid metabolism. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 115-120.	1.3	214
54	Fate and Complex Pathogenic Effects of Dioxins and Polychlorinated Biphenyls in Obese Subjects before and after Drastic Weight Loss. Environmental Health Perspectives, 2011, 119, 377-383.	2.8	170
55	Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. American Journal of Physiology - Renal Physiology, 2012, 302, G225-G235.	1.6	180
56	Predictive Factors for Ultrasonographic Grading of Non-Alcoholic Fatty Liver Disease. Hepatitis Monthly, 2012, 12, e6860.	0.1	8

#	Article	IF	Citations
57	Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 374-380.	1.3	81
58	Acute and chronic viral hepatitis. , 2012, , 361-401.		7
59	Diabetes and Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research, 2012, 2012, 1-2.	3.8	3
60	Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease. Journal of Lipids, 2012, 2012, 1-16.	1.9	35
61	The Role of Metformin in the Management of NAFLD. Experimental Diabetes Research, 2012, 2012, 1-13.	3.8	150
62	Nonalcoholic Steatohepatitis in Bariatric Patients with a Diagnosis of Obstructive Sleep Apnea. Obesity Facts, 2012, 5, 587-596.	1.6	13
63	Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation. Current Drug Metabolism, 2012, 13, 1412-1421.	0.7	55
64	Peroxisomes, Peroxisomal Diseases, and the Hepatotoxicity Induced by Peroxisomal Metabolites. Current Drug Metabolism, 2012, 13, 1401-1411.	0.7	30
65	Sex and race differences in the prevalence of fatty liver disease as measured by computed tomography liver attenuation in European American and African American participants of the NHLBI family heart study. European Journal of Gastroenterology and Hepatology, 2012, 24, 9-16.	0.8	21
66	Exogenous estrogen protects mice from the consequences of obesity and alcohol. Menopause, 2012, 19, 680-690.	0.8	7
67	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 152-161.	8.2	99
68	Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease. Asian Pacific Journal of Tropical Biomedicine, 2012, 2, 702-706.	0.5	13
69	High molecular weight persimmon tannin is a potent hypolipidemic in high-cholesterol diet fed rats. Food Research International, 2012, 48, 970-977.	2.9	51
70	Nonalcoholic Fatty Liver in Children and Adolescents: An Overview. Journal of Adolescent Health, 2012, 51, 305-312.	1.2	37
71	Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. Journal of Proteomics, 2012, 77, 27-39.	1.2	25
72	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. European Heart Journal, 2012, 33, 1190-1200.	1.0	372
73	Intravoxel Incoherent Motion Diffusion-weighted Imaging in Nonalcoholic Fatty Liver Disease: A 3.0-T MR Study. Radiology, 2012, 265, 96-103.	3.6	148
74	Elevated hematocrit in nonalcoholic fatty liver disease: A potential cause for the increased risk of cardiovascular disease?. Clinical Hemorheology and Microcirculation, 2012, 51, 59-68.	0.9	17

#	Article	IF	Citations
75	Hepatic lipomas and steatosis: An association beyond chance. European Journal of Radiology, 2012, 81, e491-e494.	1.2	14
76	Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells. Nutrition and Metabolism, 2012, 9, 34.	1.3	30
77	Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease. American Journal of Pathology, 2012, 181, 1287-1295.	1.9	35
78	Metabolic effects of lactoferrin during energy restriction and weight regain in diet-induced obese mice. Journal of Functional Foods, 2012, 4, 66-78.	1.6	36
79	Oleic acid activates peroxisome proliferator-activated receptor Î´ to compensate insulin resistance in steatotic cells. Journal of Nutritional Biochemistry, 2012, 23, 1264-1270.	1.9	32
80	Stimulation of fat accumulation in hepatocytes by PGE2-dependent repression of hepatic lipolysis, Î²-oxidation and VLDL-synthesis. Laboratory Investigation, 2012, 92, 1597-1606.	1.7	60
81	Lack of Exercise Is a Major Cause of Chronic Diseases. , 2012, 2, 1143-1211.		1,673
82	Inflammation and fibrogenesis in steatohepatitis. Journal of Gastroenterology, 2012, 47, 215-225.	2.3	123
83	Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biology and Medicine, 2012, 52, 1658-1665.	1.3	201
84	Liver X receptors bridge hepatic lipid metabolism and inflammation. Journal of Digestive Diseases, 2012, 13, 69-74.	0.7	36
85	Proteomics and gene expression analyses of mitochondria from squalene-treated apoE-deficient mice identify short-chain specific acyl-CoA dehydrogenase changes associated with fatty liver amelioration. Journal of Proteomics, 2012, 75, 2563-2575.	1.2	14
86	Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicology and Applied Pharmacology, 2012, 262, 52-59.	1.3	98
87	Association of tumor necrosis factorâ€Î± gene promoter polymorphism at sites â€308 and â€238 with nonâ€alcoholic fatty liver disease: A metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 670-676.	1.4	48
88	Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 51-56.	1.4	5
89	Activation of Liver X Receptors Attenuates Endotoxin-Induced Liver Injury in Mice with Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2012, 57, 390-398.	1.1	31
90	The Effect of Taurine on Hepatic Steatosis Induced by Thioacetamide in Zebrafish (Danio rerio). Digestive Diseases and Sciences, 2012, 57, 675-682.	1.1	26
91	Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population. Tumor Biology, 2013, 34, 3265-3269.	0.8	5
92	A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity, 2013, 21, 2138-2145.	1.5	57

#	Article	IF	Citations
93	Other Diffuse Liver Diseases: Steatosis, Hemochromatosis, etc.. , 2013, , 1027-1044.		2
94	Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatrics, 2013, 13, 40.	0.7	138
95	Current histological classification of NAFLD: strength and limitations. Hepatology International, 2013, 7, 765-770.	1.9	45
96	Clinical metabolomics paves the way towards future healthcare strategies. British Journal of Clinical Pharmacology, 2013, 75, 619-629.	1.1	89
97	Gut microbiota and non-alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection, 2013, 19, 338-348.	2.8	196
98	High-fat-cholesterol diet mainly induced necrosis in fibrotic steatohepatitis rat by suppressing caspase activity. Life Sciences, 2013, 93, 673-680.	2.0	20
99	Immune and inflammatory pathways in NASH. Hepatology International, 2013, 7, 771-781.	1.9	151
100	Utility of controlled attenuation parameter measurement for assessing liver steatosis in <scp>J</scp>apanese patients with chronic liver diseases. Hepatology Research, 2013, 43, 1182-1189.	1.8	55
101	Heterogeneity of fibrosis patterns in nonâ€alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver International, 2013, 33, 624-632.	1.9	48
102	Probucol Ameliorates the Development of Nonalcoholic Steatohepatitis in Rats Fed High-Fat Diets. Digestive Diseases and Sciences, 2013, 58, 163-171.	1.1	12
103	Toll-Like Receptors in Liver Disease. Advances in Clinical Chemistry, 2013, 59, 155-201.	1.8	75
104	Comparisons of Clinical Efficacy and Safety between the Brand- and Generic-name Fenofibrate in Patients with Hypertriglyceridemia. Journal of Experimental and Clinical Medicine, 2013, 5, 136-138.	0.2	3
105	Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. Journal of Hepatology, 2013, 59, 557-562.	1.8	186
106	Mouse KLF11 regulates hepatic lipid metabolism. Journal of Hepatology, 2013, 58, 763-770.	1.8	54
107	Endoplasmic reticulum-localized hepatic lipase decreases triacylglycerol storage and VLDL secretion. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1113-1123.	1.2	12
108	Liver steatosis assessment: Correlations among pathology, radiology, clinical data and automated image analysis software. Pathology Research and Practice, 2013, 209, 371-379.	1.0	56
109	Mitochondrial Fatty Acid Oxidation in Obesity. Antioxidants and Redox Signaling, 2013, 19, 269-284.	2.5	175
110	Modern Imaging Evaluation of the Liver. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 337-363.	0.6	6

#	Article	IF	Citations
111	Aging promotes the development of diet-induced murine steatohepatitis but not steatosis. Hepatology, 2013, 57, 995-1004.	3.6	94
112	Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology. Clinical Endocrinology, 2013, 79, 49-54.	1.2	23
113	Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clinica Chimica Acta, 2013, 424, 99-103.	0.5	279
114	Plant-Based Foods as a Source of Lipotropes for Human Nutrition: A Survey of In Vivo Studies. Critical Reviews in Food Science and Nutrition, 2013, 53, 535-590.	5.4	42
115	Supplementation of the maternal diet during pregnancy with chocolate and fructose interacts with the highâ€fat diet of the young to facilitate the onset of metabolic disorders in rat offspring. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 652-661.	0.9	11
116	Bile Acid Metabolism and Signaling. , 2013, 3, 1191-1212.		994
117	Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with Vitamin E. Free Radical Research, 2013, 47, 146-153.	1.5	34
118	Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-Î± activation. Molecular Medicine Reports, 2013, 8, 439-445.	1.1	29
119	Inhibitors of Fatty Acid Synthesis Induce PPARÎ±-Regulated Fatty AcidÎ²-Oxidative Genes: Synergistic Roles of L-FABP and Glucose. PPAR Research, 2013, 2013, 1-22.	1.1	29
120	Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARÎ±-dependent and -independent pathways. American Journal of Physiology - Renal Physiology, 2013, 304, G72-G86.	1.6	22
121	Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. American Journal of Physiology - Renal Physiology, 2013, 305, G364-G374.	1.6	63
122	Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2013, 14, 20704-20728.	1.8	325
123	Assessment of liver biopsies in obese patients. Egyptian Journal of Histology, 2013, 36, 285-291.	0.0	0
124	5-Cholesten-3Î²,25-Diol 3-Sulfate Decreases Lipid Accumulation in Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model. Molecular Pharmacology, 2013, 83, 648-658.	1.0	25
125	Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice. Journal of Lipid Research, 2013, 54, 2109-2120.	2.0	62
126	Functions of autophagy in normal and diseased liver. Autophagy, 2013, 9, 1131-1158.	4.3	384
127	PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: The NHLBI Family Heart Study. International Journal of Obesity, 2013, 37, 432-438.	1.6	49
128	Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology, 2013, 57, 1806-1813.	3.6	67

#	Article	IF	Citations
129	Cross-talk between the thyroid and liver: A new target for nonalcoholic fatty liver disease treatment. World Journal of Gastroenterology, 2013, 19, 8238.	1.4	27
130	PKCÎ´ as a Regulator for TGFÎ²1-Induced Î±-SMA Production in a Murine Nonalcoholic Steatohepatitis Model. PLoS ONE, 2013, 8, e55979.	1.1	20
131	Liver Glycerol Permeability and Aquaporin-9 Are Dysregulated in a Murine Model of Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e78139.	1.1	48
132	Nutrigenomics of High Fat Diet Induced Obesity in Mice Suggests Relationships between Susceptibility to Fatty Liver Disease and the Proteasome. PLoS ONE, 2013, 8, e82825.	1.1	39
133	Is MR Spectroscopy Really the Best MR-Based Method for the Evaluation of Fatty Liver in Diabetic Patients in Clinical Practice?. PLoS ONE, 2014, 9, e112574.	1.1	23
134	Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology. PLoS ONE, 2014, 9, e115922.	1.1	394
135	Dietary Fructose Reduction Improves Markers of Cardiovascular Disease Risk in Hispanic-American Adolescents with NAFLD. Nutrients, 2014, 6, 3187-3201.	1.7	106
136	Fatty liver in childhood. World Journal of Hepatology, 2014, 6, 33.	0.8	11
137	Hepatic Differentiated Embryo-Chondrocyte-expressed Gene 1 (Dec1) Inhibits Sterol Regulatory Element-binding Protein-1c (Srebp-1c) Expression and Alleviates Fatty Liver Phenotype. Journal of Biological Chemistry, 2014, 289, 23332-23342.	1.6	29
138	Steatosis and Steatohepatitis: Complex Disorders. International Journal of Molecular Sciences, 2014, 15, 9924-9944.	1.8	31
139	Meta-Omic Platforms to Assist in the Understanding of NAFLD Gut Microbiota Alterations: Tools and Applications. International Journal of Molecular Sciences, 2014, 15, 684-711.	1.8	26
140	Evolution of Hepatic Steatosis to Fibrosis and Adenoma Formation in Liver-Specific Growth Hormone Receptor Knockout Mice. Frontiers in Endocrinology, 2014, 5, 218.	1.5	41
141	Effects of Soothing Liver and Invigorating Spleen Recipe on Lipid Metabolism Disorders in Kupffer Cells of NAFLD Rats by LXRÎ±/SREBP-1c Signal Pathway. Chinese Herbal Medicines, 2014, 6, 297-304.	1.2	4
142	Curcumin and Liver Disease: from Chemistry to Medicine. Comprehensive Reviews in Food Science and Food Safety, 2014, 13, 62-77.	5.9	154
143	Dynamics of oxidative/nitrosative stress in mice with methionineâ€“choline-deficient diet-induced nonalcoholic fatty liver disease. Human and Experimental Toxicology, 2014, 33, 701-709.	1.1	27
144	Nonalcoholic Steatohepatitis Associated With Metabolic Syndrome. Journal of Clinical Gastroenterology, 2014, 48, 883-888.	1.1	24
145	Circulating RNA Molecules as Biomarkers in Liver Disease. International Journal of Molecular Sciences, 2014, 15, 17644-17666.	1.8	50
146	Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools. Frontiers in Immunology, 2014, 5, 177.	2.2	116

#	Article	IF	Citations
147	Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology, 2014, 59, 483-495.	3.6	220
148	Diffusion analysis with triexponential function in hepatic steatosis. Radiological Physics and Technology, 2014, 7, 89-94.	1.0	9
149	Pediatric non-alcoholic fatty liver disease: an increasing public health issue. European Journal of Pediatrics, 2014, 173, 131-139.	1.3	108
150	Nonalcoholic Fatty Liver Disease and Extra-hepatic Malignancy. Current Hepatology Reports, 2014, 13, 106-112.	0.4	0
151	Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2014, 46, 352-356.	9.4	938
152	Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology, 2014, 60, 565-575.	3.6	491
153	Bile Acid Signaling in Metabolic Disease and Drug Therapy. Pharmacological Reviews, 2014, 66, 948-983.	7.1	680
154	Effect of extracellular vesicles of human adipose tissue on insulin signaling in liver and muscle cells. Obesity, 2014, 22, 2216-2223.	1.5	128
155	Both bone marrowâ€derived and nonâ€bone marrowâ€derived cells contribute to <scp>AIM</scp>2 and <scp>NLRP</scp>3 inflammasome activation in a MyD88â€dependent manner in dietary steatohepatitis. Liver International, 2014, 34, 1402-1413.	1.9	63
156	Systems biology applied to non-alcoholic fatty liver disease (NAFLD): treatment selection based on the mechanism of action of nutraceuticals. Nutrafoods, 2014, 13, 61-68.	0.5	12
157	Persimmon Tannin accounts for hypolipidemic effects of persimmon through activating of AMPK and suppressing NF-Î°B activation and inflammatory responses in High-Fat Diet Rats. Food and Function, 2014, 5, 1536-1546.	2.1	47
158	iTRAQ-based proteomics for studying the effects of dioscin against nonalcoholic fatty liver disease in rats. RSC Advances, 2014, 4, 30704.	1.7	34
159	Persimmon tannin alleviates hepatic steatosis in L02 cells by targeting miR-122 and miR-33b and its effects closely associated with the A type ECG dimer and EGCG dimer structural units. Journal of Functional Foods, 2014, 11, 330-341.	1.6	18
160	Quantification of Hepatic Fat and Iron with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2014, 22, 397-416.	0.6	15
161	Rosiglitazone and Fenofibrate Exacerbate Liver Steatosis in a Mouse Model of Obesity and Hyperlipidemia. A Transcriptomic and Metabolomic Study. Journal of Proteome Research, 2014, 13, 1731-1743.	1.8	43
162	Polyphenols and Flavonoids in Controlling Non-Alcoholic Steatohepatitis. , 2014, , 615-623.		24
163	High susceptibility to fatty liver disease in two-pore channel 2-deficient mice. Nature Communications, 2014, 5, 4699.	5.8	164
164	Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition, 2014, 30, 915-919.	1.1	195

#	Article	IF	Citations
165	Enhanced endoplasmic reticulum SERCA activity by overexpression of hepatic stimulator substance gene prevents hepatic cells from ER stress-induced apoptosis. American Journal of Physiology - Cell Physiology, 2014, 306, C279-C290.	2.1	59
166	Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1012-1020.	1.2	50
167	A 4â€Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 632-636.	0.9	74
168	Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2014, 59, 121-129.	3.6	141
169	Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Scientific Reports, 2015, 5, 13980.	1.6	29
170	Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Scientific Reports, 2015, 5, 10096.	1.6	38
171	Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. Scientific Reports, 2015, 5, 16013.	1.6	92
172	GADD34-deficient mice develop obesity, nonalcoholic fatty liver disease, hepatic carcinoma and insulin resistance. Scientific Reports, 2015, 5, 13519.	1.6	24
173	Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Scientific Reports, 2015, 5, 12931.	1.6	127
174	Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults. Scientific Reports, 2015, 5, 12951.	1.6	40
175	Salsalate attenuates diet induced nonâ€alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. British Journal of Pharmacology, 2015, 172, 5293-5305.	2.7	29
176	Eicosapentaenoic and docosahexaenoic acid-enriched high fat diet delays the development of fatty liver in mice. Lipids in Health and Disease, 2015, 14, 74.	1.2	27
177	Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fatâ€“cholesterolâ€“sugar diet model in mice. Journal of Translational Medicine, 2015, 13, 193.	1.8	100
178	Paediatric nonâ€alcoholic fatty liver disease: an overview. Obesity Reviews, 2015, 16, 393-405.	3.1	43
179	Role of Gut Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Gastroenterology Research and Practice, 2015, 2015, 1-6.	0.7	44
180	Exercise training prevents increased intraocular pressure and sympathetic vascular modulation in an experimental model of metabolic syndrome. Brazilian Journal of Medical and Biological Research, 2015, 48, 332-338.	0.7	7
181	Non-alcoholic fatty liver disease and psoriasis: So far, so near. World Journal of Hepatology, 2015, 7, 315.	0.8	51
182	MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. Journal of Clinical Medicine, 2015, 4, 1631-1650.	1.0	53

#	Article	IF	Citations
183	Sexual Dimorphism of Adipose and Hepatic Aquaglyceroporins in Health and Metabolic Disorders. Frontiers in Endocrinology, 2015, 6, 171.	1.5	44
184	Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients. PLoS ONE, 2015, 10, e0125653.	1.1	35
185	Hugan QingzhiExerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-13.	0.5	20
186	How Inflammation Impinges on NAFLD: A Role for Kupffer Cells. BioMed Research International, 2015, 2015, 1-11.	0.9	100
187	Use of Ursodeoxycholic Acid on Post-menopausal Obesity, Hepatic steatosis and Plasma Profile as an Alternative Treatment for Hormone Replacement Therapy. Brazilian Archives of Biology and Technology, 2015, 58, 898-904.	0.5	1
188	Fenofibrate Treatment Attenuated Chronic Endoplasmic Reticulum Stress in the Liver of Nonalcoholic Fatty Liver Disease Mice. Pharmacology, 2015, 95, 173-180.	0.9	24
189	Saturated Fatty Acids Induce Post-transcriptional Regulation of HAMP mRNA via AU-rich Element-binding Protein, Human Antigen R (HuR). Journal of Biological Chemistry, 2015, 290, 24178-24189.	1.6	19
190	Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer. Medicine (United States), 2015, 94, e1718.	0.4	10
191	MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis. International Journal of Molecular Medicine, 2015, 35, 877-884.	1.8	39
192	Purified Anthocyanins from Bilberry and Black Currant Attenuate Hepatic Mitochondrial Dysfunction and Steatohepatitis in Mice with Methionine and Choline Deficiency. Journal of Agricultural and Food Chemistry, 2015, 63, 552-561.	2.4	45
193	Fatty Acids Induce a Pro-Inflammatory Gene Expression Profile in Huh-7 Cells That Attenuates the Anti-HCV Action of Interferon. Journal of Interferon and Cytokine Research, 2015, 35, 392-400.	0.5	15
194	Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a dietâ€induced mouse model of nonalcoholic fatty liver disease. Molecular Nutrition and Food Research, 2015, 59, 879-893.	1.5	102
195	The Common Marmoset as a Model for the Study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Veterinary Pathology, 2015, 52, 404-413.	0.8	19
196	Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clinica Chimica Acta, 2015, 446, 267-271.	0.5	72
197	Lactobacillus paracasei Induces M2-Dominant Kupffer Cell Polarization in a Mouse Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 2015, 60, 3340-3350.	1.1	41
198	Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Digestive Diseases and Sciences, 2015, 60, 3513-3524.	1.1	36
199	Oxidative Stress in Obesity: A Critical Component in Human Diseases. International Journal of Molecular Sciences, 2015, 16, 378-400.	1.8	654
200	Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nature Communications, 2015, 6, 7486.	5.8	317

#	Article	IF	Citations
201	Raloxifene Ameliorates Liver Fibrosis of Nonalcoholic Steatohepatitis Induced by Choline-Deficient High-Fat Diet in Ovariectomized Mice. Digestive Diseases and Sciences, 2015, 60, 2730-2739.	1.1	23
202	Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study. Drugs in R and D, 2015, 15, 21-25.	1.1	38
203	Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. European Journal of Pharmacology, 2015, 761, 405-412.	1.7	33
204	Metabonomics in Clinical Practice. Molecular and Integrative Toxicology, 2015, , 25-44.	0.5	1
205	Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity. Nutrition and Diabetes, 2015, 5, e154-e154.	1.5	33
206	Diabetes and Chocolate: Friend or Foe?. Journal of Agricultural and Food Chemistry, 2015, 63, 9910-9918.	2.4	9
207	IL-25 or IL-17E Protects against High-Fat Dietâ€“Induced Hepatic Steatosis in Mice Dependent upon IL-13 Activation of STAT6. Journal of Immunology, 2015, 195, 4771-4780.	0.4	33
208	Arylhydrocarbon receptor-dependent mIndy (Slc13a5) induction as possible contributor to benzo[a]pyrene-induced lipid accumulation in hepatocytes. Toxicology, 2015, 337, 1-9.	2.0	23
209	Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. Metabolic Syndrome and Related Disorders, 2015, 13, 393-399.	0.5	22
210	Nonalcoholic fatty liver disease â€“ current status and future directions. Journal of Digestive Diseases, 2015, 16, 541-557.	0.7	80
211	Folic acid supplementation during high-fat diet feeding restores AMPK activation via an AMP-LKB1-dependent mechanism. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R1215-R1225.	0.9	37
212	Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients. Endocrine, 2015, 48, 834-847.	1.1	64
213	Mapping of the circulating metabolome reveals Î±-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. International Journal of Obesity, 2015, 39, 279-287.	1.6	77
214	The relationship between blood urea nitrogen levels and metabolic, biochemical, and histopathologic findings of nondiabetic, nonhypertensive patients with nonalcoholic fatty liver disease. Turkish Journal of Medical Sciences, 2016, 46, 985-991.	0.4	5
215	Consumo alimentar dos portadores de DoenÃ§a HepÃ¡tica Gordurosa NÃ£o AlcoÃ³lica: comparaÃ§Ã£o entre a presenÃ§a e a ausÃªncia de Esteatoepatite NÃ£o AlcoÃ³lica e SÃndrome MetabÃ³lica. Revista De Nutricao, 2016, 29, 495-505.	0.4	3
216	The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterology Research and Practice, 2016, 2016, 1-13.	0.7	142
217	Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-7.	0.8	124
218	Euterpe edulisExtract but Not Oil Enhances Antioxidant Defenses and Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Rats. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	1.9	16

#	Article	IF	Citations
219	Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-ÎB Signaling Pathway in Type 2 Diabetic Rats. Journal of Diabetes Research, 2016, 2016, 1-10.	1.0	54
220	Korean Pine Nut Oil Attenuated Hepatic Triacylglycerol Accumulation in High-Fat Diet-Induced Obese Mice. Nutrients, 2016, 8, 59.	1.7	16
221	Gender Differences in Adipocyte Metabolism and Liver Cancer Progression. Frontiers in Genetics, 2016, 7, 168.	1.1	38
222	The Metabolic Implications of Glucocorticoids in a High-Fat Diet Setting and the Counter-Effects of Exercise. Metabolites, 2016, 6, 44.	1.3	26
223	Hepatocyte and Sertoli Cell Aquaporins, Recent Advances and Research Trends. International Journal of Molecular Sciences, 2016, 17, 1096.	1.8	26
224	Liver Disease in Pediatric Patients With Ataxia Telangiectasia. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 550-555.	0.9	28
225	Amelioration of free fatty acidâ€induced fatty liver by quercetinâ€3â€Oâ€Î²â€Dâ€glucuronide through modulation of peroxisome proliferatorâ€activated receptorâ€alpha/sterol regulatory elementâ€binding proteinâ€1c signaling. Hepatology Research, 2016, 46, 225-238.	1.8	28
226	Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 24031.	1.6	15
227	Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells. Cellular Physiology and Biochemistry, 2016, 40, 453-464.	1.1	55
228	C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. Expert Reviews in Molecular Medicine, 2016, 18, e16.	1.6	28
229	Ces3/TGH Deficiency Attenuates Steatohepatitis. Scientific Reports, 2016, 6, 25747.	1.6	33
230	Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice. Scientific Reports, 2016, 6, 31542.	1.6	32
231	A near-infrared AIEgen for specific imaging of lipid droplets. Chemical Communications, 2016, 52, 5957-5960.	2.2	93
232	Impact of high-fat diet on liver genes expression profiles in mice model of nonalcoholic fatty liver disease. Environmental Toxicology and Pharmacology, 2016, 45, 52-62.	2.0	39
233	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Digestive Diseases and Sciences, 2016, 61, 1214-1225.	1.1	130
234	Pediatric Non-alcoholic Fatty Liver Disease. Current Gastroenterology Reports, 2016, 18, 24.	1.1	32
235	Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLRâ^'/â^'.Leiden mice. International Journal of Obesity, 2016, 40, 1416-1423.	1.6	46
236	Fatty Acid Binding Proteinâ€1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias. Lipids, 2016, 51, 655-676.	0.7	41

#	Article	IF	Citations
237	Therapeutic effect of flax-based diets on fatty liver in aged laying hens. Poultry Science, 2016, 95, 2624-2632.	1.5	21
238	The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Medical Genetics, 2016, 17, 63.	2.1	29
239	ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. Journal of Molecular Endocrinology, 2016, 57, 251-260.	1.1	36
240	Gene Expression Patterns Are Altered in Athymic Mice and Metabolic Syndrome Factors Are Reduced in C57BL/6J Mice Fed High-Fat Diets Supplemented with Soy Isoflavones. Journal of Agricultural and Food Chemistry, 2016, 64, 7492-7501.	2.4	13
241	p38Î³ and p38Î´ reprogram liver metabolism by modulating neutrophil infiltration. EMBO Journal, 2016, 35, 536-552.	3.5	61
242	Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 2054-2062.	1.8	36
243	Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis. Biomedicine and Pharmacotherapy, 2016, 83, 785-791.	2.5	41
244	miRâ€212 downregulation contributes to the protective effect of exercise against nonâ€alcoholic fatty liver via targeting <scp>FGF</scp>â€21. Journal of Cellular and Molecular Medicine, 2016, 20, 204-216.	1.6	58
245	Obesity, NASH, and HCC. , 2016, , 275-286.		0
246	Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1Î². Cellular and Molecular Life Sciences, 2016, 73, 3809-3822.	2.4	12
247	Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology, 2016, 64, 1994-2014.	3.6	264
248	Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice. International Journal of Molecular Medicine, 2016, 38, 1715-1726.	1.8	49
249	Lycium barbarum polysaccharide attenuates high-fat diet-induced hepatic steatosis by up-regulating SIRT1 expression and deacetylase activity. Scientific Reports, 2016, 6, 36209.	1.6	59
250	Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. Scientific Reports, 2016, 6, 31587.	1.6	36
251	Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Scientific Reports, 2016, 6, 20848.	1.6	78
252	Statins improve NASH via inhibition of RhoA and Ras. American Journal of Physiology - Renal Physiology, 2016, 311, G724-G733.	1.6	61
253	Assessment of Vitamin D status in a group of Egyptian children with non alcoholic fatty liver disease (multicenter study). Nutrition and Metabolism, 2016, 13, 53.	1.3	12
254	Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats. Nutrition and Metabolism, 2016, 13, 63.	1.3	11

#	Article	IF	Citations
255	Dysregulated fatty acid metabolism in hepatocellular carcinoma. Hepatic Oncology, 2016, 3, 241-251.	4.2	56
256	Mutant p53 in concert with an interleukinâ€27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology, 2016, 63, 1000-1012.	3.6	29
257	Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis. Arthritis and Rheumatology, 2016, 68, 2456-2465.	2.9	47
258	Treatment with geraniol ameliorates methionineâ€cholineâ€deficient dietâ€induced nonâ€alcoholic steatohepatitis in rats. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1357-1365.	1.4	20
259	Role of BAF60a/BAF60c in chromatin remodeling and hepatic lipid metabolism. Nutrition and Metabolism, 2016, 13, 30.	1.3	21
260	Suppressing Cyclooxygenase-2 Prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway. Biochemical and Biophysical Research Communications, 2016, 469, 1034-1040.	1.0	16
261	Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biology, 2016, 8, 216-225.	3.9	127
262	Increased ratio of neutrophil elastase to Î±1â€antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 13-21.	0.9	34
264	Pathogenesis of nonalcoholic steatohepatitis. Cellular and Molecular Life Sciences, 2016, 73, 1969-1987.	2.4	151
265	Alcoholic vs non-alcoholic fatty liver in rats: distinct differences in endocytosis and vesicle trafficking despite similar pathology. BMC Gastroenterology, 2016, 16, 27.	0.8	19
266	Quantification of liver fat: A comprehensive review. Computers in Biology and Medicine, 2016, 71, 174-189.	3.9	58
267	Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity. International Journal of Obesity, 2016, 40, 675-684.	1.6	77
268	Berry intake changes hepatic gene expression and DNA methylation patterns associated with high-fat diet. Journal of Nutritional Biochemistry, 2016, 27, 79-95.	1.9	25
269	Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology, 2016, 14, 5-12.	2.4	87
270	Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radical Biology and Medicine, 2017, 111, 173-185.	1.3	101
271	Murine CD103 + dendritic cells protect against steatosis progression towards steatohepatitis. Journal of Hepatology, 2017, 66, 1241-1250.	1.8	69
272	The anti-obesity effect of fermented barley extracts with Lactobacillus plantarum dy-1 and Saccharomyces cerevisiae in diet-induced obese rats. Food and Function, 2017, 8, 1132-1143.	2.1	50
273	Pathology of nonâ€alcoholic fatty liver disease. Liver International, 2017, 37, 85-89.	1.9	247

#	Article	IF	Citations
274	Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism: Clinical and Experimental, 2017, 69, 177-187.	1.5	80
275	Hormone signaling and fatty liver in females: analysis of estrogen receptor Î± mutant mice. International Journal of Obesity, 2017, 41, 945-954.	1.6	63
276	Non-alcoholic fatty liver disease (NAFLD) â€“ pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metabolism Reviews, 2017, 49, 197-211.	1.5	414
277	Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Research, 2017, 67, 244-251.	0.7	217
278	Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid Î²-oxidation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1510-1518.	1.8	21
279	Amelioration of late-onset hepatic steatosis inIDH2-deficient mice. Free Radical Research, 2017, 51, 368-374.	1.5	8
280	Relevance of autophagy to fatty liver diseases and potential therapeutic applications. Amino Acids, 2017, 49, 1965-1979.	1.2	34
281	Serum bile acid level and fatty acid composition in Chinese children with nonâ€alcoholic fatty liver disease. Journal of Digestive Diseases, 2017, 18, 461-471.	0.7	19
282	Curcumin reduces the risk of chronic kidney damage in mice with nonalcoholic steatohepatitis by modulating endoplasmic reticulum stress and MAPK signaling. International Immunopharmacology, 2017, 49, 161-167.	1.7	24
283	Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy. Surgery for Obesity and Related Diseases, 2017, 13, 1599-1609.	1.0	18
284	PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-Î±. Future Cardiology, 2017, 13, 259-278.	0.5	120
285	Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nature Medicine, 2017, 23, 829-838.	15.2	178
286	Salicornia Extract Ameliorates Saltâ€Induced Aggravation of Nonalcoholic Fatty Liver Disease in Obese Mice Fed a Highâ€Fat Diet. Journal of Food Science, 2017, 82, 1765-1774.	1.5	14
287	TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 469-483.	2.3	53
289	Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Advances in Nutrition, 2017, 8, 240-252.	2.9	125
290	Patatin-like phospholipase domain-containing protein 3 (PNPLA3): A potential role in the association between liver disease and bipolar disorder. Journal of Affective Disorders, 2017, 209, 93-96.	2.0	9
291	Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radical Biology and Medicine, 2017, 102, 188-202.	1.3	374
293	CD40 signaling and hepatic steatosis: Unanticipated links. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 357-369.	0.7	2

#	Article	IF	Citations
294	Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Archives of Toxicology, 2017, 91, 1545-1563.	1.9	108
295	Interactive effects of chronic stress and a high-sucrose diet on nonalcoholic fatty liver in young adult male rats. Stress, 2017, 20, 608-617.	0.8	18
296	Fat fraction mapping using magnetic resonance imaging: insight into pathophysiology. British Journal of Radiology, 2018, 91, 20170344.	1.0	39
297	Biomarkers of disease can be detected in mice as early as 4 weeks after initiation of exposure to third-hand smoke levels equivalent to those found in homes of smokers. Clinical Science, 2017, 131, 2409-2426.	1.8	16
298	CTRP1 in Liver Disease. Advances in Clinical Chemistry, 2017, 79, 1-23.	1.8	15
299	NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid. Inflammation, 2017, 40, 1875-1883.	1.7	67
300	Increased incidence of nonâ€alcoholic fatty liver disease in male rat offspring exposed to fluoxetine during fetal and neonatal life involves the NLRP3 inflammasome and augmented de novo hepatic lipogenesis. Journal of Applied Toxicology, 2017, 37, 1507-1516.	1.4	8
301	Chymase inhibitor prevents the development and progression ofÂnon-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet. Journal of Pharmacological Sciences, 2017, 134, 139-146.	1.1	19
302	Systems-level organization of non-alcoholic fatty liver disease progression network. Molecular BioSystems, 2017, 13, 1898-1911.	2.9	22
303	Sake lees extract improves hepatic lipid accumulation in high fat diet-fed mice. Lipids in Health and Disease, 2017, 16, 106.	1.2	10
304	In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. Journal of Biochemical and Molecular Toxicology, 2017, 31, N/A.	1.4	21
305	Angiogenic factor with G patch and FHA domains 1 (Aggf1) promotes hepatic steatosis in mice. Biochemical and Biophysical Research Communications, 2017, 482, 134-140.	1.0	2
306	Loss of lipopolysaccharideâ€binding protein attenuates the development of dietâ€induced nonâ€alcoholic fatty liver disease in mice. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 708-715.	1.4	40
307	Berberine ameliorates nonâ€‘alcoholic steatohepatitis in ApoE-/- mice. Experimental and Therapeutic Medicine, 2017, 14, 4134-4140.	0.8	23
308	Effect of a stilbene glycosideâ€‘rich extract from Polygoni Multiflori Radix on experimental nonâ€‘alcoholic fatty liver disease based on principal component and orthogonal partial least squares discriminant analysis. Experimental and Therapeutic Medicine, 2017, 14, 4958-4966.	0.8	4
309	Redox Signaling in NASH. , 2017, , 169-180.		1
310	Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. Nutrients, 2017, 9, 1065.	1.7	49
311	Linarin Enriched Extract Attenuates Liver Injury and Inflammation Induced by High-Fat High-Cholesterol Diet in Rats. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-9.	0.5	13

#	Article	IF	Citations
312	Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. PLoS ONE, 2017, 12, e0176416.	1.1	65
313	eIF2Î± phosphorylation is required to prevent hepatocyte death and liver fibrosis in mice challenged with a high fructose diet. Nutrition and Metabolism, 2017, 14, 48.	1.3	27
314	Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis. Oncotarget, 2017, 8, 48563-48574.	0.8	18
315	How liver pathologies contribute to T1rho contrast require more careful studies. Quantitative Imaging in Medicine and Surgery, 2017, 7, 608-613.	1.1	15
316	Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. Inflammopharmacology, 2018, 26, 1103-1115.	1.9	15
317	Serum concentrations of trace elements and their relationships with paraoxonase-1 in morbidly obese women. Journal of Trace Elements in Medicine and Biology, 2018, 48, 8-15.	1.5	12
318	Deletion of NLRX1 increases fatty acid metabolism and prevents diet-induced hepatic steatosis and metabolic syndrome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1883-1895.	1.8	30
319	Dietary Patterns, Foods, Nutrients and Phytochemicals in Non-Alcoholic Fatty Liver Disease. , 2018, , 291-311.		4
320	A UPLC-MS/MS method for simultaneous quantification of pairs of oleanene- and ursane-type triterpenoid saponins and their major metabolites in mice plasma and its application to a comparative pharmacokinetic study. RSC Advances, 2018, 8, 8586-8595.	1.7	4
321	Impact of long-term continuous positive airway pressure on liver fat in male obstructive sleep apnea patients with fatty liver. Sleep and Biological Rhythms, 2018, 16, 117-124.	0.5	3
322	Human Liver Fatty Acid Binding Proteinâ€1 T94A Variant, Nonalcohol Fatty Liver Disease, and Hepatic Endocannabinoid System. Lipids, 2018, 53, 27-40.	0.7	9
323	A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. Experimental Animals, 2018, 67, 239-247.	0.7	10
324	Documento de consenso. Manejo de la enfermedad hepÃ¡tica grasa no alcohÃ³lica (EHGNA). GuÃa de prÃ¡ctica clÃnica. GastroenterologÃa Y HepatologÃa, 2018, 41, 328-349.	0.2	71
325	Sex differences in the development of hepatic steatosis in cafeteria diet-induced obesity in young mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2495-2509.	1.8	35
326	Vitamin E Supplementation in Pediatric Nonalcoholic Fatty Liver Disease. Topics in Clinical Nutrition, 2018, 33, 50-68.	0.2	2
327	Research advances in metabolism 2017. Metabolism: Clinical and Experimental, 2018, 83, 280-289.	1.5	0
328	CGplus, a standardized herbal composition ameliorates non-alcoholic steatohepatitis in a tunicamycin-induced mouse model. Phytomedicine, 2018, 41, 24-32.	2.3	9
329	Dynamic plasticity of macrophage functions in diseased liver. Cellular Immunology, 2018, 330, 175-182.	1.4	44

#	Article	IF	Citations
330	Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. Pharmacological Research, 2018, 130, 213-240.	3.1	177
331	Effects of increasing ratios of dietary omega-6/omega-3 fatty acids on human monocyte immunomodulation linked with atherosclerosis. Journal of Functional Foods, 2018, 41, 258-267.	1.6	26
332	Effects of low bisphenol A concentration on protein expression profiles in an in vitro model of non-alcoholic fatty liver disease. Molecular and Cellular Toxicology, 2018, 14, 61-70.	0.8	5
333	Ethanol Extract of Crataegus Oxyacantha L. Ameliorate Dietary Non-Alcoholic Fatty Liver Disease in Rat. Drug Research, 2018, 68, 553-559.	0.7	8
334	Food-drug interaction: Anabolic steroids aggravate hepatic lipotoxicity and nonalcoholic fatty liver disease induced by trans fatty acids. Food and Chemical Toxicology, 2018, 116, 360-368.	1.8	25
335	Caffeic acid ameliorates hepatic steatosis and reduces ER stress in high fat dietâ€“induced obese mice by regulating autophagy. Nutrition, 2018, 55-56, 63-70.	1.1	54
336	â—¾ Aquaporins within the Central Nervous System: Implications for Oedema Following Traumatic CNS Injury. , 2018, , 210-220.		1
337	Novel circulating biomarkers for nonâ€alcoholic fatty liver disease: A systematic review. Journal of Cellular Physiology, 2018, 233, 849-855.	2.0	13
338	Carboxylesterases in lipid metabolism: from mouse to human. Protein and Cell, 2018, 9, 178-195.	4.8	182
339	Preperitoneal fat as a nonâ€invasive marker of increased risk of severe nonâ€alcoholic fatty liver disease in patients with type 2 diabetes. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 511-517.	1.4	18
340	Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats. Journal of Ethnopharmacology, 2018, 212, 208-215.	2.0	25
341	Silybin inhibits NLRP3 inflammasome assembly through the NAD⁺/SIRT2 pathway in mice with nonalcoholic fatty liver disease. FASEB Journal, 2018, 32, 757-767.	0.2	81
342	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. FASEB Journal, 2018, 32, 37-51.	0.2	60
343	High regenerative capacity of the liver and irreversible injury of male reproductive system in carbon tetrachloride-induced liver fibrosis rat model. EPMA Journal, 2018, 9, 59-75.	3.3	19
344	Food components with antifibrotic activity and implications in prevention of liver disease. Journal of Nutritional Biochemistry, 2018, 55, 1-11.	1.9	62
345	Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sciences, 2018, 192, 46-54.	2.0	86
346	Downâ€regulation of lncRNAâ€NEAT1 alleviated the nonâ€alcoholic fatty liver disease via mTOR/S6K1 signaling pathway. Journal of Cellular Biochemistry, 2018, 119, 1567-1574.	1.2	67
347	iNKT cells prevent obesity-induced hepatic steatosis in mice in a C-C chemokine receptor 7-dependent manner. International Journal of Obesity, 2018, 42, 270-279.	1.6	11

#	Article	IF	Citations
348	Proteomics for studying the effects ofL. rhamnosusLV108 against non-alcoholic fatty liver disease in rats. RSC Advances, 2018, 8, 38517-38528.	1.7	9
349	Segmentation of Overlapped Steatosis in Whole-Slide Liver Histopathology Microscopy Images. , 2018, 2018, 810-813.		6
350	Effect of a high-protein diet with Î²-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial. Trials, 2018, 19, 634.	0.7	2
351	Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlrâ€/â€Leiden Mice. Hepatology Communications, 2018, 2, 1513-1532.	2.0	49
352	Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Frontiers in Physiology, 2018, 9, 1813.	1.3	68
353	Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. PLoS ONE, 2018, 13, e0207479.	1.1	3
354	Effect of Dachaihu decoction on non-alcoholic fatty liver disease model rats induced by a high-fat high-sugar diet. Journal of Traditional Chinese Medical Sciences, 2018, 5, 390-399.	0.1	1
355	Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From â€œtwo hit theoryâ€• to â€œmultiple hit modelâ€• World Journal of Gastroenterology, 2018, 24, 2974-2983.	1.4	237
356	Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 240S-247S.	0.7	10
357	Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. Oncotarget, 2018, 9, 18180-18197.	0.8	27
358	Cracking pattern of tissue slices induced by external extension provides useful diagnostic information. Scientific Reports, 2018, 8, 12167.	1.6	1
359	Differential Diagnosis of a Patient with Lysosomal Acid Lipase Deficiency: A Case Report. Laboratory Medicine, 2018, 49, 377-384.	0.8	2
360	Lipid bilayer stress-activated IRE-1 modulates autophagy during endoplasmic reticulum stress. Journal of Cell Science, 2018, 131, .	1.2	44
361	Hypoglycemic and hypolipidemic effects of triterpenoid-enriched Jamun (Eugenia jambolana) Tj ETQq1 1 0.784314 rgBT /Overlo	2.1	26
362	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. GastroenterologÃa Y HepatologÃa (English Edition), 2018, 41, 328-349.	0.0	7
363	Carbohydrates and diet patterns in nonalcoholic fatty liver disease in children and adolescents. Current Opinion in Clinical Nutrition and Metabolic Care, 2018, 21, 283-288.	1.3	18
364	Chronic moderate alcohol consumption relieves highâ€fat highâ€cholesterol dietâ€induced liver fibrosis in a rat model. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1046-1055.	0.9	9
365	Association of total testosterone, free testosterone, bioavailable testosterone and sex hormoneâ€“binding globulin with hepatic steatosis and the ratio of aspartate aminotransferase to alanine aminotransferase. Endocrine Journal, 2018, 65, 915-921.	0.7	6

#	Article	IF	Citations
366	Saxagliptin regulates M1/M2 macrophage polarization via CaMKKÎ²/AMPK pathway to attenuate NAFLD. Biochemical and Biophysical Research Communications, 2018, 503, 1618-1624.	1.0	28
367	Effect of celastrol on tollâ€‘like receptor 4â€‘mediated inflammatory response in free fatty acidâ€‘induced HepG2 cells. International Journal of Molecular Medicine, 2018, 42, 2053-2061.	1.8	21
368	Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis. Frontiers in Pharmacology, 2018, 9, 144.	1.6	9
369	Obesity, Fat Mass and Immune System: Role for Leptin. Frontiers in Physiology, 2018, 9, 640.	1.3	284
371	Galactomannan More than Pectin Exacerbates Liver Injury in Mice Fed with Highâ€Fat, Highâ€Cholesterol Diet. Molecular Nutrition and Food Research, 2018, 62, e1800331.	1.5	8
372	p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. International Journal of Molecular Sciences, 2018, 19, 921.	1.8	47
373	Insights into the Role of PPARÎ²/Î´ in NAFLD. International Journal of Molecular Sciences, 2018, 19, 1893.	1.8	42
374	Effect of Dietary Sugar Intake on Biomarkers of Subclinical Inflammation: A Systematic Review and Meta-Analysis of Intervention Studies. Nutrients, 2018, 10, 606.	1.7	87
375	Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome. Current Nutrition Reports, 2018, 7, 97-106.	2.1	135
376	The effects ofBrassica junceaL. leaf extract on obesity and lipid profiles of rats fed a high-fat/high-cholesterol diet. Nutrition Research and Practice, 2018, 12, 298.	0.7	14
377	Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis. Frontiers in Endocrinology, 2018, 9, 378.	1.5	14
378	Aquaglyceroporins: Drug Targets for Metabolic Diseases?. Frontiers in Physiology, 2018, 9, 851.	1.3	48
379	Early onset and progression of non-alcoholic fatty liver disease in young monosodium l-glutamate-induced obese mice. Journal of Developmental Origins of Health and Disease, 2019, 10, 188-195.	0.7	12
380	3â€carboxyâ€4â€methylâ€5â€propylâ€2â€furanpropanoic acid (CMPF) prevents high fat dietâ€induced insulin resistance via maintenance of hepatic lipid homeostasis. Diabetes, Obesity and Metabolism, 2019, 21, 61-72.	2.2	13
381	Sphingolipid metabolism in non-alcoholic fatty liver diseases. Biochimie, 2019, 159, 9-22.	1.3	54
382	Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review). Experimental and Therapeutic Medicine, 2019, 18, 1935-1944.	0.8	23
383	Lipoprotein Lipase Upâ€regulation in Hepatic Stellate Cells Exacerbates Liver Fibrosis in Nonalcoholic Steatohepatitis in Mice. Hepatology Communications, 2019, 3, 1098-1112.	2.0	39
384	Porphyromonas gingivalisâ€derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NFâ€ÎºB and JNK signaling pathways. Oral Diseases, 2019, 25, 1789-1797.	1.5	29

#	Article	IF	Citations
385	A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk. Journal of Nutrition, 2019, 149, 1920-1929.	1.3	59
386	The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. International Journal of Molecular Sciences, 2019, 20, 3460.	1.8	16
387	An interaction between MKL1, BRG1, and C/EBPÎ² mediates palmitate induced CRP transcription in hepatocytes. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2019, 1862, 194412.	0.9	36
388	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Digestive and Liver Disease, 2019, 51, 1586-1592.	0.4	34
389	Lipogenic SREBP-1a/c transcription factors activate expression of the iron regulator hepcidin, revealing cross-talk between lipid and iron metabolisms. Journal of Biological Chemistry, 2019, 294, 12743-12753.	1.6	13
390	NAFLD in children: new genes, new diagnostic modalities and new drugs. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 517-530.	8.2	199
391	Creosote bush-derived NDGA attenuates molecular and pathological changes in a novel mouse model of non-alcoholic steatohepatitis (NASH). Molecular and Cellular Endocrinology, 2019, 498, 110538.	1.6	8
392	Inhibition of Mitochondrial Fatty Acid Oxidation Contributes to Development of Nonalcoholic Fatty Liver Disease Induced by Environmental Cadmium Exposure. Environmental Science & Technology, 2019, 53, 13992-14000.	4.6	61
393	Mining Public Toxicogenomic Data Reveals Insights and Challenges in Delineating Liver Steatosis Adverse Outcome Pathways. Frontiers in Genetics, 2019, 10, 1007.	1.1	14
394	Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway. International Journal of Molecular Sciences, 2019, 20, 5594.	1.8	20
395	Steatosis and gut microbiota dysbiosis induced by high-fat diet are reversed by 1-week chow diet administration. Nutrition Research, 2019, 71, 72-88.	1.3	17
396	A narrative review of factors associated with the development and progression if nonâ€alcoholic fatty liver disease. GastroHep, 2019, 1, 180.	0.3	4
397	High-fat diet induces mouse liver steatosis with a concomitant decline in energy metabolism: attenuation by eicosapentaenoic acid (EPA) or hydroxytyrosol (HT) supplementation and the additive effects upon EPA and HT co-administration. Food and Function, 2019, 10, 6170-6183.	2.1	62
398	Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy. Cells, 2019, 8, 1053.	1.8	59
399	Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and Î±1 Antitrypsin. Scientific Reports, 2019, 9, 13427.	1.6	6
400	Autophagy as a molecular target of quercetin underlying its protective effects in human diseases. Archives of Physiology and Biochemistry, 2022, 128, 200-208.	1.0	39
401	Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987804.	1.4	47
402	Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. Pharmacological Research, 2019, 141, 521-529.	3.1	78

#	Article	IF	Citations
403	Epoxyeicosatrienoic acids alleviate methionineâ€cholineâ€deficient dietâ€“induced nonâ€alcoholic steatohepatitis in mice. Scandinavian Journal of Immunology, 2019, 90, e12791.	1.3	15
404	The effects of oleoylethanolamide, an endogenous PPARâ€Îł± agonist, on risk factors for NAFLD: A systematic review. Obesity Reviews, 2019, 20, 1057-1069.	3.1	35
405	Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model. International Journal of Molecular Sciences, 2019, 20, 2325.	1.8	6
406	The Complex Interactions Between Obesity, Metabolism and the Brain. Frontiers in Neuroscience, 2019, 13, 513.	1.4	80
407	Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography. European Radiology, 2019, 29, 5823-5831.	2.3	40
408	Hepatic protein Carbonylation profiles induced by lipid accumulation and oxidative stress for investigating cellular response to non-alcoholic fatty liver disease in vitro. Proteome Science, 2019, 17, 1.	0.7	11
409	Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Advances in Experimental Medicine and Biology, 2019, 1134, 33-58.	0.8	1
410	Pathogenesis of and major animal models used for nonalcoholic fatty liver disease. Journal of International Medical Research, 2019, 47, 1453-1466.	0.4	23
411	Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver axis crosstalk in an in vivo model of early obesity and NAFLD. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	93
412	MicroRNA-29a Disrupts DNMT3b to Ameliorate Diet-Induced Non-Alcoholic Steatohepatitis in Mice. International Journal of Molecular Sciences, 2019, 20, 1499.	1.8	37
413	Inhibition of TREMâ€1 attenuates inflammation and lipid accumulation in dietâ€induced nonalcoholic fatty liver disease. Journal of Cellular Biochemistry, 2019, 120, 11867-11877.	1.2	17
414	PPARÎ´ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation. Cell Death and Disease, 2019, 10, 197.	2.7	47
415	FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Scientific Reports, 2019, 9, 19785.	1.6	35
416	Characterizing the composition, metabolism and physiological functions of the fatty liver in Rana omeimontis tadpoles. Frontiers in Zoology, 2019, 16, 42.	0.9	23
417	Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins. Cells, 2019, 8, 1545.	1.8	12
418	Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. European Journal of Gastroenterology and Hepatology, 2019, 31, 859-864.	0.8	19
419	Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver. Scientific Reports, 2019, 9, 19195.	1.6	46
420	MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-ÎºB-TNFÎ± pathway. Journal of Hepatology, 2019, 70, 87-96.	1.8	129

#	Article	IF	Citations
421	Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomedicine and Pharmacotherapy, 2019, 111, 68-75.	2.5	28
422	A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters. Acta Pharmacologica Sinica, 2019, 40, 895-907.	2.8	23
423	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Advanced Science, 2019, 6, 1801585.	5.6	110
424	Molecular pathways of nonalcoholic fatty liver disease development and progression. Cellular and Molecular Life Sciences, 2019, 76, 99-128.	2.4	344
425	Modeling Disease with Human Inducible Pluripotent Stem Cells. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 449-468.	9.6	17
426	SIRT3 Deficiency Promotes Highâ€Fat Dietâ€Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis. Molecular Nutrition and Food Research, 2019, 63, e1800612.	1.5	63
427	Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity. Redox Biology, 2019, 21, 101068.	3.9	89
428	Fermented barley extracts with Lactobacillus plantarum dy-1 changes serum metabolomic profiles in rats with high-fat diet-induced obesity. International Journal of Food Sciences and Nutrition, 2019, 70, 303-310.	1.3	17
429	Higher serum carotenoids associated with improvement of non-alcoholic fatty liver disease in adults: a prospective study. European Journal of Nutrition, 2019, 58, 721-730.	1.8	30
430	Association Between Dietary Selenium Intake and the Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Journal of the American College of Nutrition, 2020, 39, 103-111.	1.1	20
431	Lipid bilayer stress and proteotoxic stress-induced unfolded protein response deploy divergent transcriptional and non-transcriptional programmes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158449.	1.2	42
432	Î²-Sitosterol mitigates the development of high-fructose diet-induced nonalcoholic fatty liver disease in growing male Sprague–Dawley rats. Canadian Journal of Physiology and Pharmacology, 2020, 98, 44-50.	0.7	16
433	Nonalcoholic fatty liver disease and use of folate. , 2020, , 323-343.		2
434	The role of genetic and epigenetic factors in non alcoholic fatty liver disease (NAFLD) pathogenesis. Meta Gene, 2020, 24, 100647.	0.3	3
435	The regulatory effects of phytosterol esters (PSEs) on gut flora and faecal metabolites in rats with NAFLD. Food and Function, 2020, 11, 977-991.	2.1	35
436	The effects of hydroalcoholic extract of spinach on prevention and treatment of some metabolic and histologic features in a rat model of nonalcoholic fatty liver disease. Journal of the Science of Food and Agriculture, 2020, 100, 1787-1796.	1.7	7
437	Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 189-206.e8.	7.2	113
438	Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet. Food and Function, 2020, 11, 9924-9935.	2.1	23

#	Article	IF	Citations
439	Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease. Free Radical Biology and Medicine, 2020, 160, 191-198.	1.3	15
440	Deep-learning-based accurate hepatic steatosis quantification for histological assessment of liver biopsies. Laboratory Investigation, 2020, 100, 1367-1383.	1.7	38
441	Effective Dose of Herbal Gold Nanoparticles for Protection of Acetaminophen-Induced Hepatotoxicity in Male Albino Rats. BioNanoScience, 2020, 10, 1094-1106.	1.5	2
442	A Gilbert syndrome-associated haplotype protects against fatty liver disease in humanized transgenic mice. Scientific Reports, 2020, 10, 8689.	1.6	8
443	TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy, 2021, 17, 2549-2564.	4.3	76
444	Discovery of Quality Markers in Hugan Qingzhi Formula by Integrating a Lipid-Lowering Bioassay with UHPLC-QQQ-MS/MS. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-10.	0.5	2
445	XBP1 links the 12-hour clock to NAFLD and regulation of membrane fluidity and lipid homeostasis. Nature Communications, 2020, 11, 6215.	5.8	34
446	Adiponectin Inhibits NLRP3 Inflammasome Activation in Nonalcoholic Steatohepatitis via AMPK-JNK/ErK1/2-NFÎºB/ROS Signaling Pathways. Frontiers in Medicine, 2020, 7, 546445.	1.2	36
447	A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicology and Applied Pharmacology, 2020, 404, 115169.	1.3	1
448	Genomic, microbial and environmental standardization in animal experimentation limiting immunological discovery. BMC Immunology, 2020, 21, 50.	0.9	11
449	A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology. Cells, 2020, 9, 2014.	1.8	27
450	Early Life Exposure to Nicotine: Postnatal Metabolic, Neurobehavioral andÂRespiratory Outcomes and the Development of Childhood Cancers. Toxicological Sciences, 2020, 178, 3-15.	1.4	18
451	Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences, 2020, 21, 7543.	1.8	6
452	Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. Hepatobiliary Surgery and Nutrition, 2020, 9, 152-169.	0.7	55
453	Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by 18F-FDG PET/CT. BMC Endocrine Disorders, 2020, 20, 75.	0.9	7
455	Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis. Frontiers in Immunology, 2020, 11, 1169.	2.2	59
456	Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in freeâ€fattyâ€acidâ€incubated HEPG2 cells and in highâ€fat dietâ€fed mice. Journal of Food Science, 2020, 85, 2216-2226.	1.5	10
457	Effects of high-fat diet on antioxidative status, apoptosis and inflammation in liver of tilapia (Oreochromis niloticus) via Nrf2, TLRs and JNK pathways. Fish and Shellfish Immunology, 2020, 104, 391-401.	1.6	65

#	Article	IF	Citations
458	Functional roles of CCL5/RANTES in liver disease. Liver Research, 2020, 4, 28-34.	0.5	20
459	Fasting C-peptide is a significant indicator of nonalcoholic fatty liver disease in obese children. Diabetes Research and Clinical Practice, 2020, 160, 108027.	1.1	12
460	Ketogenic diets and protective mechanisms in epilepsy, metabolic disorders, cancer, neuronal loss, and muscle and nerve degeneration. Journal of Food Biochemistry, 2020, 44, e13140.	1.2	48
461	Liver injury monitoring, fibrosis staging and inflammation grading using T1rho magnetic resonance imaging: an experimental study in rats with carbon tetrachloride intoxication. BMC Gastroenterology, 2020, 20, 14.	0.8	15
462	Targeting alkaline ceramidase 3 alleviates the severity of nonalcoholic steatohepatitis by reducing oxidative stress. Cell Death and Disease, 2020, 11, 28.	2.7	26
463	Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis. Microbial Pathogenesis, 2020, 142, 104009.	1.3	13
464	Pterostilbene Improves Hepatic Lipid Accumulation via the MiR-34a/Sirt1/SREBP-1 Pathway in Fructose-Fed Rats. Journal of Agricultural and Food Chemistry, 2020, 68, 1436-1446.	2.4	19
465	Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis. Hepatology, 2020, 72, 1586-1604.	3.6	19
466	Childhood obesity, cardiovascular and liver health: a growing epidemic with age. World Journal of Pediatrics, 2020, 16, 438-445.	0.8	48
467	Identification of Crucial Genetic Factors, Such as PPARÎ³, that Regulate the Pathogenesis of Fatty Liver Disease in Dairy Cows Is Imperative for the Sustainable Development of Dairy Industry. Animals, 2020, 10, 639.	1.0	16
468	GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in nonâ€alcoholic fatty liver disease via microRNAâ€200 and the MAPK pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 6107-6119.	1.6	15
469	The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease. Indian Journal of Gastroenterology, 2020, 39, 84-91.	0.7	5
470	Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome. International Journal of Molecular Sciences, 2020, 21, 2790.	1.8	37
471	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatology Communications, 2020, 4, 681-695.	2.0	28
472	The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis. Journal of Nutritional Biochemistry, 2020, 80, 108365.	1.9	12
473	Palmitic acid stimulates NLRP3 inflammasome activation through TLR4-NF-ÎºB signal pathway in hepatic stellate cells. Annals of Translational Medicine, 2020, 8, 168-168.	0.7	34
474	Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. Digestive and Liver Disease, 2021, 53, 26-34.	0.4	14
475	Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 74, 511-521.	1.8	23

#	Article	IF	Citations
476	Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin. Laboratory Investigation, 2021, 101, 369-380.	1.7	27
477	The Connection between MicroRNAs from Visceral Adipose Tissue and Non-Alcoholic Fatty Liver Disease. Acta Medica (Hradec Kralove), 2021, 64, 1-7.	0.2	3
478	Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). Microorganisms, 2021, 9, 199.	1.6	33
479	Probiotic Yogurt Fortified with Vitamin D Can Improve Glycemic Status in Non-Alcoholic Fatty Liver Disease Patients: a Randomized Clinical Trial. Clinical Nutrition Research, 2021, 10, 36.	0.5	10
480	AP39 ameliorates high fat diet-induced liver injury in young rats via alleviation of oxidative stress and mitochondrial impairment. Experimental Animals, 2021, 70, 553-562.	0.7	4
481	Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity. Nutrients, 2021, 13, 437.	1.7	23
482	Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases. Archives of Pharmacal Research, 2021, 44, 16-35.	2.7	60
483	Long-term androgen-induced nonalcoholic fatty liver disease in a polycystic ovary syndrome mouse model is related to mitochondrial dysfunction. Reproductive and Developmental Medicine, 2021, 5, 71.	0.2	3
485	Palm oil consumption and its repercussion on endogenous fatty acids distribution. Food and Function, 2021, 12, 2020-2031.	2.1	0
486	Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Frontiers in Medicine, 2021, 8, 595371.	1.2	116
487	IL-6 Reduces Mitochondrial Replication, and IL-6 Receptors Reduce Chronic Inflammation in NAFLD and Type 2 Diabetes. International Journal of Molecular Sciences, 2021, 22, 1774.	1.8	22
488	Efficacy and safety of drugs for nonalcoholic steatohepatitis. Journal of Digestive Diseases, 2021, 22, 72-82.	0.7	15
489	Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. Scientific Reports, 2021, 11, 5050.	1.6	10
490	Differentially expressed proteins obtained by labelâ€free quantitative proteomic analysis reveal affected biological processes and functions in Western dietâ€induced steatohepatitis. Journal of Biochemical and Molecular Toxicology, 2021, 35, 1-11.	1.4	7
491	Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients. Journal of Personalized Medicine, 2021, 11, 238.	1.1	15
492	Qinghua Fang inhibits high-fat diet-induced non-alcoholic fatty liver disease by modulating gut microbiota. Annals of Palliative Medicine, 2021, 10, 3219-3234.	0.5	4
493	Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacological Research, 2021, 166, 105517.	3.1	16
494	Sterol Ferulate Rich Wheat Bran Oil Concentrate Prevents Liver Damage in MAFLD Mouse Model by Modulating FAS and PCSK9. ACS Food Science & Technology, 2021, 1, 644-652.	1.3	2

#	Article	IF	Citations
495	Effects of several tea extracts on nonalcoholic fatty liver disease in mice fed with a highâ€fat diet. Food Science and Nutrition, 2021, 9, 2954-2967.	1.5	12
496	Relationship between NAFLD and Periodontal Disease from the View of Clinical and Basic Research, and Immunological Response. International Journal of Molecular Sciences, 2021, 22, 3728.	1.8	18
497	Perinatal exposure to di-(2-ethylhexyl) phthalate induces hepatic lipid accumulation mediated by diacylglycerol acyltransferase 1. Human and Experimental Toxicology, 2021, 40, 1698-1709.	1.1	8
498	Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats. Journal of Steroid Biochemistry and Molecular Biology, 2021, 208, 105829.	1.2	22
499	The influence of PM2.5 exposure on non-alcoholic fatty liver disease. Life Sciences, 2021, 270, 119135.	2.0	30
500	Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development. Current Drug Discovery Technologies, 2021, 18, 333-353.	0.6	5
501	Membrane lipids and transporter function. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166079.	1.8	31
502	PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease. Cell Metabolism, 2021, 33, 1187-1204.e9.	7.2	60
503	Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions. International Journal of Molecular Sciences, 2021, 22, 6777.	1.8	23
504	The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review. Frontiers in Medicine, 2021, 8, 644594.	1.2	5
505	Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. Inflammation Research, 2021, 70, 765-776.	1.6	8
506	Omegaâ€3 phospholipids and obesityâ€associated NAFLD: Potential mechanisms and therapeutic perspectives. European Journal of Clinical Investigation, 2022, 52, e13650.	1.7	9
507	Periodontal diseaseâ€"related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oralâ€liver axis. Periodontology 2000, 2021, 87, 204-240.	6.3	44
508	A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health. Medical Science Monitor, 2021, 27, e934134.	0.5	11
509	Aldehyde Dehydrogenase Mutation Exacerbated High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease with Gut Microbiota Remodeling in Male Mice. Biology, 2021, 10, 737.	1.3	6
510	Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. Journal of Integrative Medicine, 2021, 19, 545-554.	1.4	19
511	Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases. Cell Metabolism, 2021, 33, 1911-1925.	7.2	91
512	Zonarol Protected Liver from Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in a Mouse Model. Nutrients, 2021, 13, 3455.	1.7	6

#	Article	IF	Citations
513	Retrospective analysis (2009â€“2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102261.	1.8	2
514	Proteome analysis identified proteins associated with mitochondrial function and inflammation activation crucially regulating the pathogenesis of fatty liver disease. BMC Genomics, 2021, 22, 640.	1.2	3
515	Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. Nutrients, 2021, 13, 3135.	1.7	51
516	An adverse outcome pathway based in vitro characterization of novel flame retardants-induced hepatic steatosis. Environmental Pollution, 2021, 289, 117855.	3.7	27
517	Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. Metabolism: Clinical and Experimental, 2021, 124, 154873.	1.5	28
518	Secondary hyperlipidemia: features of manifestation in various somatic diseases. Profilakticheskaya Meditsina, 2021, 24, 105.	0.2	2
519	The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 375-383.	0.7	10
520	Ganoderma lucidum polysaccharides improve insulin sensitivity by regulating inflammatory cytokines and gut microbiota composition in mice. Journal of Functional Foods, 2017, 38, 545-552.	1.6	69
521	C-Jun/C7ORF41/NF-Î²B axis mediates hepatic inflammation and lipid accumulation in NAFLD. Biochemical Journal, 2020, 477, 691-708.	1.7	14
522	Gut microbiota and systemic immunity in health and disease. International Immunology, 2021, 33, 197-209.	1.8	34
525	Nonalcoholic fatty liver associated with impairment of kidney function in nondiabetes population.. Biochemia Medica, 2012, 22, 92-99.	1.2	26
526	Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight, 2017, 2, .	2.3	62
527	Peroxisomal Î²-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. JCI Insight, 2018, 3, .	2.3	61
528	Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBPÎ±. Journal of Clinical Investigation, 2015, 125, 3809-3818.	3.9	84
529	Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity. Journal of Clinical Investigation, 2017, 127, 2855-2867.	3.9	79
530	Regular Exercise Is Associated with a Reduction in the Risk of NAFLD and Decreased Liver Enzymes in Individuals with NAFLD Independent of Obesity in Korean Adults. PLoS ONE, 2012, 7, e46819.	1.1	142
531	Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans. PLoS ONE, 2013, 8, e82163.	1.1	149
532	Effect of Diet on Expression of Genes Involved in Lipid Metabolism, Oxidative Stress, and Inflammation in Mouse Liverâ€“Insights into Mechanisms of Hepatic Steatosis. PLoS ONE, 2014, 9, e88584.	1.1	71

#	Article	IF	Citations
533	C-C Chemokine Receptor 2 Inhibitor Ameliorates Hepatic Steatosis by Improving ER Stress and Inflammation in a Type 2 Diabetic Mouse Model. PLoS ONE, 2015, 10, e0120711.	1.1	21
534	Impact of Obstructive Sleep Apnea on Liver Fat Accumulation According to Sex and Visceral Obesity. PLoS ONE, 2015, 10, e0129513.	1.1	11
535	Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis. PLoS ONE, 2016, 11, e0149783.	1.1	84
536	The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis. PLoS ONE, 2017, 12, e0169740.	1.1	36
537	New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans. PLoS ONE, 2017, 12, e0172900.	1.1	52
538	Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways. PLoS ONE, 2017, 12, e0184282.	1.1	27
539	Urinary neutrophil gelatinase-associated lipocalin (uNGAL) levels in patients with nonalcoholic fatty liver disease. Interventional Medicine & Applied Science, 2012, 4, 132-138.	0.2	3
540	Zingiber officinale formulation reduces hepatic injury and weight gain in rats fed an unhealthy diet. Anais Da Academia Brasileira De Ciencias, 2019, 91, e20180975.	0.3	9
541	The Role of Visceral Adipose Tissue in the Pathogenesis of Non-alcoholic Fatty Liver Disease. European Endocrinology, 2010, 7, 96.	0.8	15
542	Chronically high level of tgfb1a induction causes both hepatocellular carcinoma and cholangiocarcinoma via a dominant Erk pathway in zebrafish. Oncotarget, 2017, 8, 77096-77109.	0.8	25
543	A porcine placental extract prevents steatohepatitis by suppressing activation of macrophages and stellate cells in mice. Oncotarget, 2018, 9, 15047-15060.	0.8	14
544	Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription ofsrebp1. Oncotarget, 2016, 7, 36207-36219.	0.8	34
545	IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget, 2016, 7, 33649-33661.	0.8	55
546	Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy. Current Medicinal Chemistry, 2015, 22, 2991-3012.	1.2	41
547	Modulation of Aquaporins by Dietary Patterns and Plant Bioactive Compounds. Current Medicinal Chemistry, 2019, 26, 3457-3470.	1.2	10
548	IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression. Current Drug Targets, 2015, 16, 1315-1323.	1.0	71
549	Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances. Current Molecular Pharmacology, 2017, 10, 207-225.	0.7	66
550	Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. Caspian Journal of Internal Medicine, 2020, 11, 346-354.	0.1	3

#	Article	IF	Citations
551	Effects of Obesity on Axillary Lymph Node Structure: Association of Hilar Fat Deposition and Alterations in Cortex Width. MÃ¦dica, 2020, 15, 99-104.	0.4	5
552	Bile salt hydrolase-overexpressing Lactobacillus strains can improve hepatic lipid accumulation in vitro in an NAFLD cell model. Food and Nutrition Research, 2020, 64, .	1.2	15
553	Recent Progress of Proteomics in Nonalcoholic Fatty Liver Disease*. Progress in Biochemistry and Biophysics, 2011, 38, 487-498.	0.3	1
554	Potential role ofHelicobacter pyloriinfection in nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2013, 19, 7024.	1.4	41
555	High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World Journal of Gastroenterology, 2014, 20, 8525.	1.4	116
556	Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors. World Journal of Gastroenterology, 2015, 21, 2875.	1.4	8
557	Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. World Journal of Gastroenterology, 2015, 21, 7529.	1.4	35
558	Autophagy activation by Jiang Zhi Granule protects against metabolic stress-induced hepatocyte injury. World Journal of Gastroenterology, 2018, 24, 992-1003.	1.4	15
559	Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World Journal of Gastroenterology, 2020, 26, 6141-6162.	1.4	77
560	Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. Hepatobiliary Surgery and Nutrition, 2014, 3, 377-85.	0.7	31
561	Prevalence of Nonalcoholic Fatty Liver Disease and its Related Metabolic Risk Factors in Isfahan, Iran. Advanced Biomedical Research, 2017, 6, 47.	0.2	18
562	THS Toxins Induce Hepatic Steatosis by Altering Oxidative Stress and SIRT1 Levels. , 2016, 06, .		6
563	MicroRNAs in hepatic pathophysiology in diabetes. World Journal of Diabetes, 2011, 2, 158.	1.3	7
564	Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. World Journal of Hepatology, 2016, 8, 211.	0.8	15
565	Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2013, 4, 4.	0.6	10
566	Pediatric Nonalcoholic Fatty Liver Disease. , 0, , .		1
567	Steatosis and steatohepatitis found in adults after death due to non-burn trauma. Clinics, 2019, 74, e1070.	0.6	2
568	Neutrophil infiltration regulates clock-gene expression to organize daily hepatic metabolism. ELife, 2020, 9, .	2.8	26

#	Article	IF	Citations
569	Effects of Lingonberry (Vaccinium vitis-idaea L.) Supplementation on Hepatic Gene Expression in High-Fat Diet Fed Mice. Nutrients, 2021, 13, 3693.	1.7	8
570	Copper (Cu) induced changes of lipid metabolism through oxidative stress-mediated autophagy and Nrf2/PPARÎ³ pathways. Journal of Nutritional Biochemistry, 2022, 100, 108883.	1.9	42
571	PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 439-448.	0.7	1
572	Sarcopenia in Non-alcoholic Steatohepatitis (NASH). Current Hepatology Reports, 0, , 1.	0.4	0
573	A Preliminary Application of Magnetic Resonance Spectroscopy for Quantitatively Assessing Hepatic Fat and the Efficacy of Anti-obesity Therapy. Journal of Analytical Science and Technology, 2011, 2, 187-193.	1.0	0
574	Mouse Models to Study the Effect of Natural Products on Obesity-Associated NAFLD/NASH. Energy Balance and Cancer, 2015, , 247-270.	0.2	1
575	Serum Adipokines in Patients with Non-alcoholic Fatty Liver Disease - Is there a Role for Predicting the Severity of Liver Disease?. Internal Medicine: Open Access, 2015, 05, .	0.0	0
576	The Antioxidant, Anti-inflammatory, and Antiapoptotic Effects of Wolfberry in Fatty Liver Disease. , 2015, , 45-63.		0
578	Basic Understanding of Inflammation. , 2015, , 21-28.		0
579	Deposition features of heterovalent iron (Fe2 + and Fe3 +) in the liver in alcoholic and nonalcoholic steatohepatitis. PatologÃ¤, 2015, .	0.1	0
580	Heart Disease and the Liver: Interactions Between the Heart and the Liver. , 2016, , 179-202.		0
582	G-Aminobutyric acid promotes methionine-choline deficient diet-induced nonalcoholic steatohepatitis. Journal of Biomedical Research, 2017, 31, 65.	0.7	3
583	Bile Acids and NAFLD/NASH. , 2017, , 145-155.		0
584	Relative and combined Effects of Ethanol and Hepatitis C Virus Infection on Serum Interleukin-17 Levels. Archives of Hepatitis Research, 2017, 3, 013-018.	0.4	0
585	Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterologia, 2017, 51, 188-195.	0.0	4
586	Development of a non-invasive model to improve the accuracy of determining liver fibrosis stage inÂnonalcoholic fatty liver disease. Gastroenterologia, 2017, 51, 256-271.	0.0	1
587	Correction of L-carnitine insufficiency in non-alcoholic steatohepatitis. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 2018, 2018, 16-21.	0.0	0
588	The role of cannabinoid receptor 1 in the development of oxidative/nitrosative stress in mice with non-alcoholic fatty liver disease. Medicinski Podmladak, 2019, 70, 1-8.	0.2	0

#	Article	IF	Citations
589	Association between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. Journal of Gastrointestinal Infections, 2019, 9, 5-9.	0.1	0
590	Salivary and Urinary Metabolome in Pediatric Obesity and Metabolic Syndrome. , 2020, , 249-263.		0
591	Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease. Cells, 2021, 10, 2978.	1.8	14
592	Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease. Frontiers in Cellular and Infection Microbiology, 2020, 10, 581888.	1.8	8
593	Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi Journal of Gastroenterology, 2021, 27, 319-330.	0.5	10
594	DEVELOPMENT THE PHYSICAL QUALITIES OF PERSONS WITH HEALTH DISORDERS AND FORMATION THE HUMAN RESERVE OF THE STATE. Likars'ka Sprava, 2020, , 72-76.	0.2	0
595	Imaging methods in the assessment of nonalcoholic fatty liver disease. Radiologia Brasileira, 2020, 53, IX-X.	0.3	1
596	Expression of fatty acid synthase in nonalcoholic fatty liver disease. International Journal of Clinical and Experimental Pathology, 2010, 3, 505-14.	0.5	111
597	Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease. International Journal of Clinical and Experimental Pathology, 2011, 4, 661-6.	0.5	9
598	Signal transductions and nonalcoholic fatty liver: a mini-review. International Journal of Clinical and Experimental Medicine, 2014, 7, 1624-31.	1.3	49
599	Hepatic fat accumulation and regulation of FAT/CD36: an effect of hepatic irradiation. International Journal of Clinical and Experimental Pathology, 2014, 7, 5379-92.	0.5	17
601	Assessment of Subclinical Myocardial Changes in Non-Alcoholic Fatty Liver Disease: A Case-Control Study Using Speckle Tracking Echocardiography. Iranian Journal of Medical Sciences, 2018, 43, 466-472.	0.3	6
602	Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation. International Journal of Clinical and Experimental Pathology, 2017, 10, 8119-8129.	0.5	1
603	Resveratrol Reduces Lipid Accumulation through Upregulating the Expression of MicroRNAs Regulating Fatty Acid Bet Oxidation in Liver Cells: Evidence from and Studies. Iranian Journal of Pharmaceutical Research, 2020, 19, 333-340.	0.3	0
604	Nonalcoholic steatohepatitis critically rewires the ischemia/reperfusion-induced dysregulation of cardiolipins and sphingolipids in mice. Hepatobiliary Surgery and Nutrition, 2023, 12, 3-19.	0.7	2
605	The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement?. Nutrients, 2021, 13, 4014.	1.7	18
606	Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation. IScience, 2021, 24, 103449.	1.9	14
607	Gut microbiome profiling in nonalcoholic fatty liver disease and healthy individuals in Indonesian population. Journal of Medical Sciences (Taiwan), 2022, 42, 166.	0.1	1

#	Article	IF	Citations
608	A novel function of CREG in metabolic disorders. Medical Review, 2022, .	0.3	1
609	Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 1102.	1.8	8
610	Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. Signal Transduction and Targeted Therapy, 2022, 7, 11.	7.1	104
611	MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Frontiers in Medicine, 2021, 8, 774079.	1.2	15
612	Lentinan Supplementation Protects the Gutâ€“Liver Axis and Prevents Steatohepatitis: The Role of Gut Microbiota Involved. Frontiers in Nutrition, 2021, 8, 803691.	1.6	23
613	Limonin Alleviates Non-alcoholic Fatty Liver Disease by Reducing Lipid Accumulation, Suppressing Inflammation and Oxidative Stress. Frontiers in Pharmacology, 2021, 12, 801730.	1.6	9
614	3-tert-Butyl-4-hydroxyanisole Impairs Hepatic Lipid Metabolism in Male Mice Fed with a High-Fat Diet. Environmental Science & Technology, 2022, 56, 3204-3213.	4.6	16
615	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	1.8	54
616	Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. Asian Pacific Journal of Tropical Biomedicine, 2022, 12, 99.	0.5	4
617	Correlation between serum total bile acid and nonalcoholic fatty liver disease: A cross-sectional study. Saudi Journal of Gastroenterology, 2022, 28, 304.	0.5	1
618	Role of natural products as therapeutic option against nonalcoholic fatty liver disease. , 2022, , 289-305.		0
619	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human. Molecular and Cellular Proteomics, 2022, 21, 100225.	2.5	7
620	Substrate Stiffness-Driven Membrane Tension Modulates Vesicular Trafficking via Caveolin-1. ACS Nano, 2022, 16, 4322-4337.	7.3	22
621	Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease. Molecular Biology Reports, 2022, 49, 5927-5937.	1.0	4
622	Lactobacillus plantarum MA2 Ameliorates Methionine and Choline-Deficient Diet Induced Non-Alcoholic Fatty Liver Disease in Rats by Improving the Intestinal Microecology and Mucosal Barrier. Foods, 2021, 10, 3126.	1.9	12
623	Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). Cureus, 2021, 13, e20776.	0.2	6
624	Protective effect of isoflavones and triterpenoid saponins from pueraria lobata on liver diseases: A review. Food Science and Nutrition, 2022, 10, 272-285.	1.5	12
625	Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice With High-Fat Diet-Induced Non-alcoholic Steatohepatitis. Frontiers in Physiology, 2021, 12, 783341.	1.3	4

#	Article	IF	Citations
626	FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism. Frontiers in Pharmacology, 2022, 13, 850128.	1.6	1
635	Histological and immunohistochemical assessment of liver biopsies in morbidly obese patients. Histology and Histopathology, 2012, 27, 459-66.	0.5	12
637	Receptor-interacting protein kinase-1 ablation in liver parenchymal cells promotes liver fibrosis in murine NASH without affecting other symptoms. Journal of Molecular Medicine, 2022, , 1.	1.7	2
638	Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics. World Journal of Clinical Pediatrics, 2022, 11, 221-238.	0.6	7
639	Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo. Journal of Ethnopharmacology, 2022, 295, 115382.	2.0	4
640	Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology. Biomedicines, 2022, 10, 1315.	1.4	4
641	The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Biomedicines, 2022, 10, 1487.	1.4	9
642	A Prediction Model of the Incidence of Nonalcoholic Fatty Liver Disease With Visceral Fatty Obesity: A General Population-Based Study. Frontiers in Public Health, 0, 10, .	1.3	1
643	Transforming growth factorâ€beta 1: A new factor reducing hepatic SHBG production in liver fibrosis. Journal of Cellular Physiology, 0, , .	2.0	1
644	Acyl-CoA:diacylglycerol acyltransferase: Properties, physiological roles, metabolic engineering and intentional control. Progress in Lipid Research, 2022, 88, 101181.	5.3	27
645	The role of gut microflora dysbiosis in clinical manifestation of patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.. International Journal of Scientific Research and Management, 2022, 10, 658-667.	0.0	0
646	Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology. Middle East Journal of Digestive Diseases, 2022, 14, 167-181.	0.2	2
647	Dietary omega-6/omega-3 ratio is not associated with gut microbiota composition and disease severity in patients with nonalcoholic fatty liver disease. Nutrition Research, 2022, 107, 12-25.	1.3	2
648	Non-Alcoholic Fatty Liver Disease and Steatohepatitis. , 2023, , 610-621.		2
649	Deep Learning Based Steatosis Quantification of Liver Histopathology Images Using Unsupervised Feature Extraction. , 2022, , .		0
650	Therapeutic potential and research progress of diosgenin for lipid metabolism diseases. Drug Development Research, 2022, 83, 1725-1738.	1.4	2
651	Targeting mitochondrial quality control of T cells: Regulating the immune response in HCC. Frontiers in Oncology, 0, 12, .	1.3	3
652	Role of liquid fructose/sucrose in regulating the hepatic transcriptome in a high-fat Western diet model of NAFLD. Journal of Nutritional Biochemistry, 2023, 112, 109174.	1.9	3

#	Article	IF	Citations
653	Pathophysiological Role of Chymase-Activated Matrix Metalloproteinase-9. Biomedicines, 2022, 10, 2499.	1.4	5
654	Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review. European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48, 1-10.	0.6	3
655	N-end Ruleâ€“Mediated Proteasomal Degradation of ATGL Promotes Lipid Storage. Diabetes, 2023, 72, 210-222.	0.3	2
656	Fatty Liver Disease: A Crosstalk Between Lipid Species. European Medical Journal Hepatology, 0, , 76-83.	1.0	0
657	Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Diabetes and Metabolism Journal, 2022, 46, 829-842.	1.8	7
658	Automated Segmentation and Morphological Characterization of Hepatic Steatosis and Correlation with Histopathology. Journal of Clinical and Experimental Hepatology, 2022, , .	0.4	0
660	Therapeutic Potential of Herbal medicine against Non-alcoholic Fatty Liver Disease. Current Drug Targets, 2023, 24, .	1.0	0
661	Recognizing Mitochondrial Hepatopathy in Acute Fatty Liver of Pregnancy. Gastroenterology, Hepatology and Endoscopy Practice, 2023, 3, 7.	0.1	0
663	Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2023, 2023, 1-13.	0.8	3
664	Relative Enhancement in Gadoxetate Disodium-Enhanced Liver MRI as an Imaging Biomarker in the Diagnosis of Non-Alcoholic Fatty Liver Disease in Pediatric Obesity. Nutrients, 2023, 15, 558.	1.7	0
665	Associations of altered hepatic gene expression in American lifestyle-induced obesity syndrome diet-fed mice with metabolic changes during NAFLD development and progression. Journal of Nutritional Biochemistry, 2023, 115, 109307.	1.9	5
666	From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria. Biology, 2023, 12, 595.	1.3	3
667	Non-Neoplastic Disorders of the Liver. , 2024, , 489-556.		0
668	Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya. BMJ Open Gastroenterology, 2023, 10, e001044.	1.1	1
669	Bioactive Compounds as Inhibitors of Inflammation, Oxidative Stress and Metabolic Dysfunctions via Regulation of Cellular Redox Balance and Histone Acetylation State. Foods, 2023, 12, 925.	1.9	8
670	Diets, Gut Microbiota and Metabolites. Phenomics, 2023, 3, 268-284.	0.9	4
671	Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis. Hepatitis Monthly, 2023, 23, .	0.1	6
673	Circulating Short-Chain Fatty Acids and Non-Alcoholic Fatty Liver Disease Severity in Patients with Type 2 Diabetes Mellitus. Nutrients, 2023, 15, 1712.	1.7	6

#	Article	IF	Citations
674	The role of ChREBP in carbohydrate sensing and NAFLD development. Nature Reviews Endocrinology, 2023, 19, 336-349.	4.3	9
675	Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice. Antioxidants, 2023, 12, 971.	2.2	1
683	Endocrine. , 2023, , 107-203.		0
687	Acyl CoA oxidase: from its expression, structure, folding, and import to its role in human health and disease. Molecular Genetics and Genomics, 0, , .	1.0	1
697	Metabolic-Associated Fatty Liver Disease: Opportunistic Screening at CT Colonography. , 2023, , 277-290.		0